Comparative Pharmacology
Head-to-head clinical analysis: DARICON versus HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DARICON versus HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE.
DARICON vs HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Daricon (oxyphencyclimine) is a competitive antagonist of muscarinic acetylcholine receptors (M1-M5), inhibiting parasympathetic nerve impulses. It reduces gastrointestinal motility, gastric acid secretion, and smooth muscle spasm by blocking cholinergic activity at effector cells.
Hydrocodone is a mu-opioid receptor agonist; homatropine methylbromide is an anticholinergic that reduces gastrointestinal motility and secretions.
5 mg orally three times daily. Maximum dose: 15 mg per day.
1 tablet (containing homatropine methylbromide 5 mg and hydrocodone bitartrate 5 mg) orally every 4 to 6 hours as needed for cough. Maximum 6 tablets per 24 hours.
None Documented
None Documented
Terminal elimination half-life: 12-18 hours; clinical context: allows twice-daily dosing
Hydrocodone: Terminal elimination half-life 3.8-6.4 hours (mean ~4.5 h) in adults; prolonged in hepatic/renal impairment (up to 12-15 h). Homatropine methylbromide: Terminal half-life ~4-6 hours via quaternary structure limiting CNS penetration.
Renal (70% unchanged, 30% as metabolites); biliary/fecal (10%)
Hydrocodone: Renal excretion of metabolites (hydromorphone, norhydrocodone) as glucuronide conjugates (~60%) and unchanged drug (<10%). Biliary/fecal elimination accounts for ~20-30%. Homatropine methylbromide: Predominantly fecal elimination via biliary excretion as unchanged quaternary ammonium compound (~70-80%); renal excretion of unchanged drug (~10-20%).
Category C
Category D/X
Anticholinergic
Anticholinergic